Phase I clinical trial of antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of advanced pleural mesothelioma

被引：0
|
作者：
Hassan, R.
Sharon, E.
Chen, H. X.
Conlon, K.
Ling, A.
Steinberg, S. M.
Pastan, I.
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] NCI, CTEP, Bethesda, MD 20892 USA
[3] NIH, Bethesda, MD 20892 USA
[4] NCI, Biostat & Data Management Sect, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17518
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer
    Ma, CX
    Nair, S
    Thomas, S
    Mandrekar, SJ
    Nikcevich, DA
    Rowland, KM
    Fitch, TR
    Windschitl, HE
    Hillman, SL
    Schild, SE
    Jett, JR
    Obasaju, C
    Adjei, AA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 5929 - 5937
  • [22] Phase I trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients with advanced nonsquamous non small cell lung cancer or malignant pleural mesothelioma.
    Zucali, Paolo Andrea
    Simonelli, Matteo
    De Vincenzo, Fabio
    Fatuzzo, Giuseppe
    Bertossi, Monica
    Perrino, Matteo
    Miggiano, Chiara
    Giordano, Laura
    Bonifacio, Cristiana
    Sposta, Federica Mrakic
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial
    West, H. L.
    Wakelee, H. A.
    Perry, M. C.
    Belt, R. J.
    Chen, R.
    Obasaju, C.
    ANNALS OF ONCOLOGY, 2009, 20 (05) : 850 - 856
  • [24] Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I–II trial
    G P Stathopoulos
    J Dimitroulis
    D Antoniou
    C Katis
    D Tsavdaridis
    O Armenaki
    C Marosis
    P Michalopoulou
    T Grigoratou
    J Stathopoulos
    British Journal of Cancer, 2005, 93 : 1106 - 1111
  • [25] Phase I study of SS1P a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers
    Hassan, Raffit
    Bullock, Susie
    Premkumar, Ahalya
    Kreitman, Robert J.
    Kindler, Hedy
    Willingham, Mark C.
    Pastan, Ira
    CLINICAL CANCER RESEARCH, 2007, 13 (17) : 5144 - 5149
  • [26] Pemetrexed in combination with cisplatin versus carboplatin as first-line therapy in patients with advanced-stage malignant pleural mesothelioma (MPM): A systematic review and meta-analysis.
    Srour, Samer Ali
    Stoner, Julie A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™) and cisplatin:: A multicenter phase II trial
    Manegold, C
    Gatzemeier, U
    von Pawel, J
    Pirker, R
    Malayeri, R
    Blatter, J
    Krejcy, K
    ANNALS OF ONCOLOGY, 2000, 11 (04) : 435 - 440
  • [28] Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial
    Stathopoulos, GP
    Dimitroulis, J
    Antoniou, D
    Katis, C
    Tsavdaridis, D
    Armenaki, O
    Marosis, C
    Michalopoulou, P
    Grigoratou, T
    Stathopoulos, J
    BRITISH JOURNAL OF CANCER, 2005, 93 (10) : 1106 - 1111
  • [29] Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial
    Ceresoli, Giovanni L.
    Aerts, Joachim G.
    Dziadziuszko, Rafal
    Ramlau, Rodryg
    Cedres, Susana
    van Meerbeeck, Jan P.
    Mencoboni, Manlio
    Planchard, David
    Chella, Antonio
    Crino, Lucio
    Krzakowski, Maciej
    Russel, Jorn
    Maconi, Antonio
    Gianoncelli, Letizia
    Grosso, Federica
    LANCET ONCOLOGY, 2019, 20 (12): : 1702 - 1709
  • [30] Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial.
    McCleod, M
    Treat, J
    Christiansen, NP
    Mintzer, DM
    Bonomi, P
    Bloss, LP
    Taylor, L
    Monberg, MJ
    Ye, Z
    Obasaju, CK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 650S - 650S
12345